According to GuruFocus Insider Data, the recent Chief Financial Officer (CFO) buys were for RCM Technologies Inc. (RCMT, Financial), Digirad Corp (DRAD, Financial) and Cellectar Biosciences Inc. (CLRB).
RCM Technologies Inc. CFO Kevin D. Miller bought 150,000 shares
CFO Kevin D. Miller bought 150,000 shares for $1.20 per share on June 2. Since then, the stock price has increased by 62.5%. RCM Technologies Inc. has a market cap of $22.04 million and its shares were traded around $1.95. The company has a price-sales ratio of 0.14.
RCM Technologies Inc. announced its first-quarter results with revenue of $45.03 million and gross profit of $10.84 million, while the net loss was $5.95 million. The 2019 total revenue was $191.10 million, a 0.5% decrease from 2018. The gross profit was $48.59 million, a 1% decrease from the year prior. The net loss was $4.06 million.
Director Roger H. Ballou bought 100,000 shares for $1.20 per share on June 2. Since then, the stock price has increased by 62.5%.
Bradley Vizi bought 850,000 shares for $1.20 per share on June 2. Since then, the stock price has increased by 62.5%.
Digirad Corp Chief Operating Officer and CFO David J. Noble bought 20,000 shares
Chief Operating Officer and CFO David J. Noble bought 20,000 shares for $2.24 per share on May 28. Since then, the stock price has increased by 34.82%. Digirad Corp has a market cap of $13.060 million and its shares were traded around $3.02. The company has a price-sales ratio of 0.05.
Digirad Corp announced its first-quarter results with revenue of $28.86 million and gross profit of $4.44 million, while the net loss was $2.95 million. The 2019 total revenue was $114.19 million, a 10% increase from 2018. The gross profit was $22.12 million, a 7% increase from the year prior. The net loss was $4.63 million.
President and CEO Matthew G. Molchan bought 2,000 shares for $2.24 per share on May 28. Since then, the stock price has increased by 34.82%.
Director Jeffrey E. Eberwein bought 44,000 shares for $2.24 per share on May 28. Since then, the stock price has increased by 34.82%.
Director Michael A. Cunnion bought 5,000 shares for $2.24 per share on May 28. Since then, the stock price has increased by 34.82%.
Director Mitchell I Quain bought 22,000 shares for $2.24 per share on May 28. Since then, the stock price has increased by 34.82%.
Cellectar Biosciences Inc. CFO Dov Elefant bought 4,348 shares
CFO Dov Elefant bought 4,348 shares for $1.15 per share on June 5. Since then, the stock price has increased by 2.61%. Cellectar Biosciences Inc. has a market cap of $11.080 million and its shares were traded around $1.18. Over the past 10 years, Cellectar Biosciences Inc. had an annual average earnings growth of 57.00%.
President and CEO James V. Caruso bought 21,740 shares for $1.15 per share on June 5. Since then, the stock price has increased by 2.61%.
Chief Business Officer Jarrod Longcor bought 65,218 shares for $1.15 per share on June 5. Since then, the stock price has increased by 2.61%.
Director Stephen A. Hill bought 18,000 shares for $1.08 per share on June 4. Since then, the stock price has increased by 9.26%.
Disclosure: none
Not a Premium Member of GuruFocus? Sign up for a free 7-day trial here.
